These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 16831406)
1. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts. Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406 [TBL] [Abstract][Full Text] [Related]
2. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039 [TBL] [Abstract][Full Text] [Related]
4. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780 [TBL] [Abstract][Full Text] [Related]
5. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples]. Hüseyin A; Sancak B; Arikan S Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710 [TBL] [Abstract][Full Text] [Related]
6. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878 [TBL] [Abstract][Full Text] [Related]
7. [Biofilm production and antifungal susceptibility patterns of Candida species]. Yücesoy M; Karaman M Mikrobiyol Bul; 2004; 38(1-2):91-8. PubMed ID: 15293907 [TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of oral Candida to seven antifungal agents. Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594 [TBL] [Abstract][Full Text] [Related]
9. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726 [TBL] [Abstract][Full Text] [Related]
10. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613 [TBL] [Abstract][Full Text] [Related]
11. Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method. Pai MP; Jones AL; Mullen CK Diagn Microbiol Infect Dis; 2007 May; 58(1):129-32. PubMed ID: 17240112 [TBL] [Abstract][Full Text] [Related]
12. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest. Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981 [TBL] [Abstract][Full Text] [Related]
13. [Studies on microtiter broth dilution method for antifungal susceptibility testing of yeast isolates from blood and cerebrospinal fluid]. Fujita S Rinsho Byori; 1996 Apr; 44(4):373-8. PubMed ID: 8847821 [TBL] [Abstract][Full Text] [Related]
14. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006. Yang YL; Wang AH; Wang CW; Cheng WT; Li SY; Lo HJ; Diagn Microbiol Infect Dis; 2008 Jun; 61(2):175-80. PubMed ID: 18304773 [TBL] [Abstract][Full Text] [Related]
15. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study. Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K; Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267 [TBL] [Abstract][Full Text] [Related]
16. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis. Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100 [TBL] [Abstract][Full Text] [Related]
17. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). Swinne D; Watelle M; Van der Flaes M; Nolard N Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180 [TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of 115 isolates of Candida to amphotericin B, fluconazole and itraconazole. Mallié M; Bastide JM Drugs Exp Clin Res; 1996; 22(6):301-7. PubMed ID: 9034756 [TBL] [Abstract][Full Text] [Related]
19. Study of the susceptibility of yeast isolates of clinical interest to five antifungal agents using the E test. Linares MJ; Muñoz JF; Solís F; Rodríguez FC; Valero A; Casal M Rev Esp Quimioter; 1998 Mar; 11(1):64-9. PubMed ID: 9795292 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital. Arikan S; Sancak B; Hascelik G Med Mycol; 2005 Mar; 43(2):171-8. PubMed ID: 15832560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]